Back HBV Treatment

HBV Treatment

AASLD Issues Updated Practice Guidelines for Management of Chronic Hepatitis B

The American Association for the Study of Liver Diseases (AASLD) published a revised version of its "Practice Guidelines for Management of Chronic Hepatitis B" in the September 2009 issue of Hepatology. Key changes are new recommendations for first-line and second-line antiviral therapy, reflecting the latest research on hepatitis B virus (HBV) treatment and the recent approval of tenofovir (Viread) for this indication.

Read more:

Should Entecavir (Baraclude) and Tenofovir (Viread) Be First-line Treatment for Chronic Hepatitis B?

At the annual Digestive Disease Week (DDW 2009) meeting this week in Chicago, a panel of experts discussed the prevention and management of antiviral drug resistance in patients receiving long-term treatment for chronic hepatitis B virus (HBV) infection, according to DDW Daily News, the official conference newspaper.

Read more:

Addition of Emtricitabine (Emtriva) Does Not Improve Response to Tenofovir (Viread) for Chronic Hepatitis B

As described in a poster presented at the 44th Annual Meeting of the European Association for the Study of the Liver (EASL 2009) last month in Copenhagen, T. Berg and an international team of colleagues conducted Study 106, comparing the efficacy of tenofovir/emtricitabine combination therapy versus tenofovir alone for the treatment of chronic hepatitis B.

Read more:

Investigational 2-Dose Dynavax Heplisav Hepatitis B Vaccine May Work Better than Standard 3-Dose Energix-B Vaccine

An investigational hepatitis B virus (HBV) vaccine may offer the same degree of protection with 2 doses as the standard Engerix-B vaccine does with 3 doses, according to a study presented at the 44th Annual Meeting of the European Association for the Study of the Liver (EASL 2009) last month in Copenhagen.

Read more:

Some Individuals Harbor HBV with Adefovir and Tenofovir Resistance Mutations before They Ever Receive Treatment

Several nucleoside/nucleotide drugs have potent activity against hepatitis B virus (HBV), but the virus can rapidly develop resistance, presenting a barrier to long-term treatment success.

Read more: